Bristol Fundamentals

Delisted . USA . 
Stock . Bristol-Myers Squibb
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Pink Sheet. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers pink sheet.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Bristol Total Asset Analysis

Bristol Myers' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Total Asset 
 = 
Tangible Assets 
+ 
Intangible Assets 
More About Total Asset | All Equity Analysis

Current Bristol Myers Total Asset

    
  109.31 B  
Most of Bristol Myers' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
Competition

Based on the latest financial disclosure, Bristol Myers Squibb has a Total Asset of 109.31 B. This is much higher than that of the Healthcare sector and 161.05% higher than that of the Drug Manufacturers - Major industry. The total asset for all United States stocks is significantly lower than that of the firm.

Bristol-Myers Squibb Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.
Bristol Myers Squibb is the top company in revenue category among related companies. It is number one stock in total asset category among related companies fabricating about  2.36  of Total Asset per Revenue. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bristol Myers by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bristol Myers' Pink Sheet . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.

Bristol Cash per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Cash per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.
Bristol Myers is currently under evaluation in cash per share category among related companies.

Bristol Fundamentals

Revenue46.38 B
EBITDA20.1 B
Net Income7.01 B
Cash and Equivalents6.07 B
Cash per Share3.72 X
Total Debt39.6 B
Debt to Equity59.40 %
Current Ratio1.40 X
Book Value Per Share7.55 X
Cash Flow from Operations16.21 B
Number of Employees23.7 K
Beta0.35
Market Capitalization2110.59 B
Total Asset109.31 B
Annual Yield0.0012 %
Net Asset109.31 B
Last Dividend Paid1.59

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol Myers without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Piotroski F Score Now

   

Piotroski F Score

Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
All  Next Launch Module

Pair Trading with Bristol Myers

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.

Other Consideration for investing in Bristol Pink Sheet

If you are still planning to invest in Bristol-Myers Squibb check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bristol Myers' history and understand the potential risks before investing.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites


 
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2023 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY